Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
A. Cometta, T. Calandra, H. Gaya, S. H. Zinner, R. De Bock, A. Del Favero, G. Bucaneve, F. Crokaert, W. V. Kern, J. Klastersky, J. Langenaeken, A. Micozzi, A. Padmos, M. Paesmans, C. Viscoli, M. P. Glauser, P. Martino, D. Caballero, W. V. Kern, D. EngelhardM. Shapiro, E. Castagnola, L. Massimo, R. Giacchino, M. Sanz, M. Giacchino, M. Aoun, B. Oppenheim, D. D'Antonio, F. Follath, G. Barbabietola, F. Menichetti, M. Montillo, M. T. Van Lint, A. Cometta, B. Gibson, L. Resegotti, C. Kibbler, H. Prentice, A. Van Hoof, H. Van Landuyt, P. Ricci, G. Rosti, A. Efremidis, F. Di Raimondo, R. Hemmer, M. Hatjiyanni, B. Seitanides, D. Amsallen, J. M. Estavoyer, G. Petrikkos, A. Porcellini, Z. Berneman
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer'. Together they form a unique fingerprint.